Description du projet
Un nouveau dispositif pour les crises d’épilepsie nocturnes
Plus de 50 millions de personnes dans le monde souffrent d’épilepsie et moins d’un tiers d’entre elles ne trouvent que peu ou pas de soulagement grâce aux médicaments, notamment en ce qui concerne les crises nocturnes. Le projet NightWatch, financé par l’UE, est un dispositif médical enregistré sans fil qui détecte et notifie les soignants à distance en cas de crise nocturne grave, en quelques secondes. Le dispositif comprend un bracelet qui mesure la fréquence cardiaque et les mouvements, créant ainsi un algorithme unique. Testé cliniquement, l’appareil peut détecter plus de 90 % de tous les types de crises nocturnes urgentes, ce qui en fait le système le plus fiable disponible.
Objectif
More than 50M people worldwide suffer from epilepsy, characterized by uncontrolled seizures, and about 30% find no relief from those despite taking medication. Nocturnal seizures can be critical; each year at least 33.000 people in EU die of Sudden Unexpected Death in Epilepsy (SUDEP), 40% of which could be prevented by attending the seizures on time. This is a continuous challenge for patients and caregivers, with important social and societal consequences (anxiety, depression, lack of sleep), and high intramural care costs (over €20 billion per year in EU).
The NightWatch is a registered medical device that detects and notifies wirelessly remote caregivers in case of heavy nocturnal seizures in just few seconds. The bracelet uses a combination of heart rate and movement measurement, a unique AI algorithm conceived by three Dutch institutes specialised in epilepsy, automatically adapting to different patient patterns to minimize false alarm rate. It has been clinically tested and can detect > 90% of all types of urgent nocturnal seizures making it the most reliable system available.
The NightWatch targets caregivers, patients and professionals who seek an effective alarm system for severe nocturnal seizures. It improves their quality of life giving them peace of mind, higher level of independency, reduces cost of care by reducing the need for intramural attention, and prevents deaths caused by SUDEP. With a trend to-wards home care and self-monitoring pushing market growth (expected to reach €4.0 billion in 2019), wearables becoming the preferred type of seizure monitoring. EU leads the seizure monitor devices market (46%), followed by North America (28%).
NightWatch is the flagship product of LivAssured, a Dutch company created in 2013 as a spin-off to take over the commercial exploitation of the research results of the Tele-Epilepsy Consortium on nocturnal seizures. With its full commercial exploitation, we expect an accumulated profit of €19M and a ROI of 4
Champ scientifique
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
5261AD VUGHT
Pays-Bas
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.